San Diego-primarily based Viking Therapeutics marked itself as a serious competitor during the weight loss drug industry in February after revealing promising info from the mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injection and in March the company u